Marker Therapeutics, Inc. (NASDAQ:MRKR) Sees Large Growth in Short Interest

Marker Therapeutics, Inc. (NASDAQ:MRKR) saw a large growth in short interest in January. As of January 31st, there was short interest totalling 232,100 shares, a growth of 20.0% from the January 15th total of 193,400 shares. Currently, 3.0% of the company’s stock are sold short. Based on an average trading volume of 72,900 shares, the short-interest ratio is presently 3.2 days.

Insider Activity

In other Marker Therapeutics news, Director Steve Elms purchased 11,085 shares of Marker Therapeutics stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average price of $3.20 per share, for a total transaction of $35,472.00. Following the completion of the acquisition, the director now owns 325,370 shares of the company’s stock, valued at approximately $1,041,184. This trade represents a 3.53 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Enterprise Associates 16 New purchased 554,250 shares of Marker Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were acquired at an average price of $3.20 per share, with a total value of $1,773,600.00. Following the acquisition, the insider now directly owns 1,625,678 shares of the company’s stock, valued at $5,202,169.60. This trade represents a 51.73 % increase in their position. The disclosure for this purchase can be found here. 17.35% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Marker Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Alyeska Investment Group L.P. acquired a new position in Marker Therapeutics during the fourth quarter valued at approximately $2,847,000. Blue Owl Capital Holdings LP bought a new stake in shares of Marker Therapeutics during the fourth quarter worth $1,724,000. Aisling Capital Management LP grew its stake in shares of Marker Therapeutics by 3.5% during the fourth quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock worth $1,012,000 after buying an additional 11,084 shares during the last quarter. LPL Financial LLC bought a new stake in shares of Marker Therapeutics during the fourth quarter worth $248,000. Finally, Northern Trust Corp grew its stake in shares of Marker Therapeutics by 66.9% during the fourth quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock worth $168,000 after buying an additional 21,703 shares during the last quarter. 22.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MRKR has been the subject of several research reports. Brookline Capital Management upgraded shares of Marker Therapeutics to a “strong-buy” rating in a research report on Monday, February 10th. LADENBURG THALM/SH SH raised their price objective on shares of Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a research report on Monday, October 21st.

Marker Therapeutics Stock Up 1.2 %

Shares of NASDAQ MRKR traded up $0.02 during midday trading on Monday, reaching $1.72. The company’s stock had a trading volume of 61,990 shares, compared to its average volume of 78,471. Marker Therapeutics has a fifty-two week low of $1.48 and a fifty-two week high of $5.99. The business’s 50 day moving average price is $2.81 and its two-hundred day moving average price is $3.18.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.